1. Home
  2. JFIN vs CRBP Comparison

JFIN vs CRBP Comparison

Compare JFIN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$2.16

Market Cap

149.7M

Sector

Finance

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$8.97

Market Cap

168.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
CRBP
Founded
2011
2009
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.7M
168.3M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
JFIN
CRBP
Price
$2.16
$8.97
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
62.6K
275.0K
Earning Date
06-03-2026
05-08-2026
Dividend Yield
17.47%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$116.00
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
97.62
52 Week Low
$2.12
$7.12
52 Week High
$14.70
$20.56

Technical Indicators

Market Signals
Indicator
JFIN
CRBP
Relative Strength Index (RSI) 22.96 45.94
Support Level N/A $7.86
Resistance Level $4.54 $9.73
Average True Range (ATR) 0.14 0.47
MACD 0.02 -0.04
Stochastic Oscillator 7.68 25.00

Price Performance

Historical Comparison
JFIN
CRBP

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: